Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2018 Complete Response Letters: Efficacy Issues Drove Most Product Rejections

Executive Summary

US FDA issued at least seven rejections to novel products; opioid analgesic sponsors had very little success, while biosimilar developers had a so-so year.

Advertisement

Related Content

Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA
Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out
Akcea Waylivra's Surrogate Endpoint Gains Support At US FDA Advisory Committee
Surrogate Endpoint, Safety Questions May Be Too Much For Waylivra To Overcome At US FDA Panel
InfaCare’s Stannsoporfin For Jaundice Rebuked By US FDA Panel
Keeping Track Of Bad News: Alkermes' Depression Candidate Gets Refuse To File; Teva/Celltrion Biosimilars Land CRLs
Braeburn Gets CRL For CAM2038 In Opioid Use Disorder, Yields Ground To Indivior

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel